

# Vaccines Market Forecast to Grow at 5.6% CAGR from 2024 to 2031 | SkyQuest Technology

Growing Prevalence of Viral Infectious Diseases to Help Vaccines Market Register 5.6% CAGR by 2031



WESTFORD, MA, UNITED STATES, September 27, 2024 /

EINPresswire.com/ -- Growing Prevalence of Viral Infectious Diseases to Help <u>Vaccines Market</u> Register 5.6% CAGR by 2031

Vaccines are the most powerful and cost-effective way to protect millions of people worldwide. They have the potential to transform health by removing the burden of life-threatening infectious diseases from the populations of the developing countries. World Health Organization says vaccination awareness and government policy strains have helped prevent 2-3 million deaths per year. Further investments, as well as the corporate mergers and consolidations, increase production and sales worldwide. One of the biggest challenges organizations and companies face worldwide is trial and error in effectively combating malaria, HIV, and tuberculosis pharmaceutical companies.

# Get a Free Sample Research Report:

https://www.skyquestt.com/sample-request/vaccine-market

# Segmental Analysis

By Technology type - Recombinant & Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Others

By Indication - Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, & Rubella, Diphtheria, Pertussis, & Tetanus {DPT}, Polio, Hepatitis, Other Indications

By End User - Pediatric, Adults, Travelers

By Region - North America, U.S., Canada, Mexico, Europe, Germany, UK, France, Italy, Spain, Rest of Europe, Asia-Pacific, Japan, China, India, Australia, Rest of Asia-Pacific, LAMEA, Brazil, Saudi Arabia, South Africa, Rest of LAMEA

Competitive Environment in the Vaccines Market: An Enlarged View

The vaccines marketplace is a dynamic and competitive environment, with the huge installed pharmaceuticals and rising biotechnology companies competing for market proportion. Key marketplace players are focusing on developing the new vaccines, expanding product traces, and forming the strategic partnerships to reinforce their positions on this developing segment.

#### Ask for Customization:

https://www.skyquestt.com/speak-with-analyst/vaccine-market

This report covers the following players:

- AstraZenecea
- CSL Limited
- Emergent BioSolutions Inc.
- GSK
- "Johnson &
- Johnson"
- Merck & Co., Inc.
- Novartis
- Novavax, Inc.
- Pfizer
- Sanofi Aventis
- Serum Institute of India Ltd

## Dominance of Leading Pharmaceutical Companies

The global vaccine market is dominated by pharmaceutical giants such as Pfizer, GlaxoSmithKline (GSK), Sanofi and Merck. These companies have abundant resources, large research and development (R&D) capabilities, and the well-established distribution networks that give them a competitive advantage. Their ability to develop, test and bring vaccines to market has positioned them as leaders, in response to the public health emergencies.

# Strategic Cooperation and Partnership

Strategic collaborations between the companies are an important determinant in the vaccines market. Established pharmaceutical agencies to pool resources and expertise in partnerships with the smaller biotechnology companies, research institutes, and government agencies. These collaborations have been critical to speed up vaccine development and production.

February 2024: UNICEF expanded cooperation with the Ministry of Health in Azerbaijan to increase childhood immunization coverage.

February 2024: UNICEF Africa and CDC expand their collaboration to strengthen supply chain management, primary health care and immunization coverage among African children. January 2023: Bharat Biotech offered iNCOVAC, a domestically manufactured COVID-19 oral vaccine for adults over 18 years.

August 2022: GSK acquired Affinivax, Inc., a clinical biopharmaceutical company. Through this acquisition, the company aims to strengthen its manufacturing portfolio.

View report summary and Table of Contents (TOC): <a href="https://www.skyquestt.com/report/vaccine-market">https://www.skyquestt.com/report/vaccine-market</a>

This report covers the following segments:

- A. Age
- 1. Pediatric
- 2. Adult
- B. Disease
- 1. Cancer
- 2. Hepatitis
- 3. Pneumococcal disease
- 4. DTP
- 5. Influenza
- 6. Human Papilloma Virus
- 7. Meningococcal Disease
- 8. Polio
- 9. Rotavirus
- 10. COVID-19
- 11. Others
- C. Technology
- 1. Conjugated
- 2. Live
- 3. Inactivated
- 4. Recombinant
- 5. Toxoid
- 6. Others

Pioneering the Future of Vaccines and Innovations Shaping Global Health
The vaccines market is at the forefront of innovation, with advances in mRNA technology,
nanotechnology and viral vector platforms changing the landscape as global health challenges,
such as emerging infectious diseases and pandemic threats. Furthermore, vaccination coverage
and personalized vaccine delivery methods highlight the ongoing progress in vaccine
developments. The future of vaccination marks a new era of global health improvement driven
by scientific advances and collaborative efforts of the promise.

## Related Reports:

<u>Digital Vaccine Market</u> is growing at a CAGR of 10.66% during the forecast period (2024-2031).

### About Us:

SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences,

CleanTech, AgriTech, NanoTech and Information & Communication Technology.

We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.

Visit Our Website: <a href="https://www.skyquestt.com/">https://www.skyquestt.com/</a>

Mr. Jagraj Singh Skyquest Technology Consulting Pvt. Ltd. +1 351-333-4748 email us here Visit us on social media: LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/747038732

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.